Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel polymeric micelles plus gemcitabine as neoadjuvant therapy for non-metastatic locally advanced pancreatic cancer
ChiCTR2600134825Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Primary endpoint: Major pathological response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600134825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134825.